Mohamed Saad Zaghloul

Prof. Mohamed Saad Zaghloul

Children's Cancer Hospital, Egypt, Cairo, Al Qāhirah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
MZMohamed Saad Zaghloul
Mohamed Saad Zaghloul
ANAkram Nouh
Akram Nouh
MNMohamed Nazmy
Mohamed Nazmy
SRSamy Ramzy
Samy Ramzy
AZAshraf S. Zaghloul
Ashraf S. Zaghloul
EKEhab Mohamed Khalil
Ehab Mohamed Khalil

1 April 2010 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MZMohamed Saad Zaghloul
Mohamed Saad Zaghloul
RBRimoun Boutrus
Rimoun Boutrus
HEHisham El-Hossieny
Hisham El-Hossieny
YKYasser Abdel Kader
Yasser Abdel Kader
IEInas El-Attar
Inas El-Attar
MNMohamed Nazmy
Mohamed Nazmy

1 April 2014 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MZMohamed Saad Zaghloul
Mohamed Saad Zaghloul
EEEman Eldebawy
Eman Eldebawy
SASoha Ahmed
Soha Ahmed
AMAmr G. Mousa
Amr G. Mousa
AAAmr Amin
Amr Amin
MSMohamed Sabry
Mohamed Sabry

1 December 2012 in Journal of the Egyptian National Cancer Institute
Verified
Journal Article
Open access
MZMohamed Saad Zaghloul
Mohamed Saad Zaghloul
Schistosoma-associated bladder cancer was believed, for several decades, to be a completely unique entity of disease, different from urothelial cancer. This was probably due to its distinct clinicopathologic and demographic features that varied from those of urothelial entity. The carcinogenesis is an extremely complex process resulting from the accumulation of many genetic and epigenetic changes leading to alterations in the cell proliferation regulation process. In bladder cancer, many of these carcinogenic cascades were not fully documented or somewhat conflicting. Inspite of the efforts performed, much is still needed to explore the presence or absence of the carcinogenic difference with a different etiology. The control of schistosomiasis in certain countries and the subsequent decrease in the intensity of infestation showed changing of features approaching that of urothelial tumors. However the schistosoma-associated bladder cancer presented in more advanced stages than schistosoma-non associated urothelial cancer. More recently, data are gathered that, upon applying the same treatment protocol and management care, stage by stage comparison of the treatment end-results were found to be similar in bladder cancer patients with a different etiology. All treatment options; including radical cystectomy with or without adjuvant or neoadjuvant chemo- or radiotherapy or trimodality bladder preserving treatment seem to lead to similar end-results regardless of etiologic factor(s) implicated in bladder cancer development.

4 December 2019 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
WRWafaa Rashed
Wafaa Rashed
EMEslam Maher
Eslam Maher
MAMohamed Adel
Mohamed Adel
OSOssama Saber
Ossama Saber
MZMohamed Saad Zaghloul
Mohamed Saad Zaghloul

30 November 2020 in Journal of the Egyptian National Cancer Institute
Verified
Journal Article
Open access
PDF file
MZMohamed Saad Zaghloul
Mohamed Saad Zaghloul
TZTarek M. Zaghloul
Tarek M. Zaghloul
MBMai K. Bishr
Mai K. Bishr
BBBrian C. Baumann
Brian C. Baumann
Background: Urinary schistosomiasis and its severe complications, mainly bladder cancer, are scarce in non-endemic areas. The deficiency in knowledge and clinical experience of schistosomiasis may lead to inadequate management. Highlighting these topics may be of value, especially with the increased immigration from endemic low-/middle-income countries (LMIC) to non-endemic high-income countries (HIC). Schistosomiasis is a parasitic infection endemic in many low- and middle-income countries. It can affect various systems but is best known for its effect on the urinary system. Main Body: PubMed, Scopus, Google Scholar, and the Cochrane Library databases were searched for urinary schistosomiasis and its related bladder cancer published from 1980 till 2020. Schistosoma haematobium (SH) infecting the urinary bladder was considered by the IARC as group 1 definitive biological carcinogenic agent. Several carcinogenic pathways have been postulated but the exact mechanism(s) are not defined yet. A more thorough understanding of the parasite life cycle was explored to help eradicate the infection especially for the immigrants from endemic areas. This may prevent or slow down the process of carcinogenesis that leads to Schistosoma-associated bladder cancer (SA-BC), which is usually, but not conclusively, squamous cell carcinoma. Treatment of SA-BC generally follows the same guidelines as urothelial Schistosoma-non-associated bladder cancer (SNA-BC) management; however, prospective trials to confirm and refine the treatment approach for SA-BC have been relatively limited. Conclusion: The available data showed that despite some etiologic and carcinogenic differences, the oncologic outcomes are generally comparable for SA-BC and NSA-BC when adjusting for stage, risk status, and comorbidities.